Trends in Gabapentin Prescribing for Addiction
Physicians are increasingly prescribing gabapentin to patients undergoing treatment for substance use disorders despite a lack of strong clinical evidence confirming its effectiveness in these settings. A national study published in Drug and Alcohol Dependence shows that prescribing rates for the medication nearly doubled between 2016 and 2023. Researchers examined data from over 200,000 urine drug tests collected across all 50 U.S. states to map how and when this drug is being used by vulnerable patient populations.
Gabapentin is approved by the Food and Drug Administration to treat partial seizures and specific forms of nerve pain. Clinicians frequently use it off-label to help patients manage withdrawal symptoms or co-occurring issues such as insomnia and anxiety. Many providers consider it a safer alternative to addictive classes like benzodiazepines or opioids. Yet, medical literature remains thin regarding the drug's actual impact on recovery outcomes for people with substance use disorders.
Data Analysis of Patient Drug Testing
Matthew S. Ellis, a researcher at Washington University in St. Louis, led the study alongside experts from the testing laboratory Millennium Health. They reviewed 206,161 urine specimens submitted between January 2016 and October 2023. By using liquid chromatography-tandem mass spectrometry, the team isolated chemical components to identify the presence of specific substances. They compared these findings against official medication lists provided by clinical staff.
The final results revealed that 5.9 percent of the patient sample held a valid prescription for gabapentin. Prescribing rates grew from 3.9 percent in 2016 to 7.6 percent in 2023. Older patients and those with private insurance were the most likely to receive a prescription. Among clinical populations, patients struggling with sedative use disorders received these authorizations at higher rates than those with other primary diagnoses.
Unprescribed Use and Polysubstance Patterns
Unprescribed use of gabapentin remains higher than authorized usage, appearing in 11.3 percent of the studied urine samples. This suggests that a significant number of individuals in treatment obtain the medication through channels outside of their formal care plan. While unprescribed use remains prevalent, the data showed a downward trend, falling from 15.2 percent in 2016 to 9.9 percent in 2023.
Patients taking the drug without a prescription frequently test positive for other substances. Detection rates for fentanyl, cocaine, and methamphetamine were higher in the unprescribed group compared to those with a valid prescription. This heavy overlap suggests that gabapentin often forms part of a broader cycle of polysubstance use. Whether this reflects self-medication strategies or intentional drug mixing is a primary concern for future clinical research.
Limitations and Future Outlook
Researchers acknowledged that the study relies on specimens submitted to one laboratory, which may limit the broad application of these findings to every clinic in the country. The accuracy of the findings rests on the completeness of the medication lists submitted by providers. If a clinic failed to record a prescription, the data would misclassify an authorized user as an unprescribed one. Furthermore, urine testing cannot distinguish between a patient following a doctor’s dosage instructions and one misusing a valid prescription.
The broader context of this study underscores a conflict in current addiction medicine. Clinicians seek alternatives to high-risk drugs, but they often adopt new practices before high-quality trials confirm safety. As use continues to rise, investigators need to determine if gabapentin is helping patients stabilize or if it contributes to hidden risks within the substance use treatment system.